Dispute mounts over Sanofi-Synthelabo's partnership with Zuellig

Published: 2004-09-08 06:59:00

Updated: 2004-09-08 06:59:00

President Christian Stoeckling at Zuellig Pharma Korea said in its September 3 statement that Sanofi-Synthelabo Korea has decided to select Zuellig as one of the main outsourcing partners and from this September 1, Sanofi-Synthelabo Korea's whole drugs should be entirely supplied by Zuellig, clai...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK